Amylin (AMLN), Lilly (LLY) Get Marketing Approval from EC for BYETTA with Basal Insulin Treatment
Go back to Amylin (AMLN), Lilly (LLY) Get Marketing Approval from EC for BYETTA with Basal Insulin Treatment| Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) | Delayed: 30.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.98 | 52 Week High | $31.02 | |||
| Open | $3.30 | 52 Week Low | $8.03 | |||
| Day High | $30.98 | P/E | N/A | |||
| Day Low | $30.98 | EPS | $-4.38 | |||
| Volume | 440,704 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1244.40 -35.94 (2.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1280.34 | 52 Week High | $88.16 | |||
| Open | $1274.13 | 52 Week Low | $67.88 | |||
| Day High | $1280.28 | P/E | 288.06 | |||
| Day Low | $1243.23 | EPS | $4.32 | |||
| Volume | 2,621,172 | |||||
